Novartis Receives EMA’s CHMP Positive Opinion Recommending Marketing Authorization of Cosentyx (secukinumab) for Hidradenitis Suppurativa
Shots:
- The EMA’s CHMP has adopted a positive opinion recommending marketing authorization of Cosentyx. The opinion was based on the P-III trials (SUNSHINE) & (SUNRISE) evaluating Cosentyx (300mg, q2w/q4w) vs PBO in 545 & 544 patients across 40 countries
- In both trials, patients treated with Cosentyx (300mg, q2w) achieved HiSCR (45.0% vs 33.7%) & (42.3% vs 31.2%) @16wks.; (46.1% vs 31.2%) & (41.8% vs 33.7%) with Cosentyx (300mg, q4w). Treatment response rates continued to improve beyond the 1EPs analysis @16wk.
- ≥55% achieved a HiSCR measure @52wk., ≥50% reduction in pain. The safety results were consistent with the well-established profile of Cosentyx & have been submitted to the US FDA with decisions expected in 2023
Ref: Novartis | Image: Novartis
Related News:- Novartis Published P-III (SUNSHINE) and (SUNRISE) Trials Results of Cosentyx (secukinumab) for Hidradenitis Suppurativa in The Lancet
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
